Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference

New York, April 24, 2018 -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it will be presenting at the Eighth Annual BioNJ BioPartnering Conference on Thursday, May 3, 2018.

Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics, said, “We are pleased to have the chance to present at the BioNJ BioPartnering conference and to update the local healthcare community on Intrommune Therapeutics’ progress.”

Intrommune’s lead product candidate, INT-301, is being developed for the treatment of peanut allergy. INT-301 is based on the oral mucosal immunotherapy (OMIT) platform, which enables daily administration of treatment to desensitize a patient to peanuts while the patient brushes their teeth. Peanut allergy is a potentially deadly disease which affects 1.5 million American children, costing families of patients $6 billion per year. There is currently no approved treatment for this condition.

In March, Intrommune’s technology licensor, Allovate Therapeutics, announced the issuance of Japan Patent Number JP6239066 titled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” This is the second Japanese OMIT patent in Intrommune’s IP portfolio, which also includes issued and pending patents in other key market territories across the globe.

In addition to peanut allergy, Intrommune plans to develop OMIT treatments for other common food allergies. Although more than 170 foods have been reported to cause allergic reactions, there are a key group of eight foods – milk, egg, peanut, tree nuts, wheat, soy, fish and crustacean shellfish – that are responsible for most of the serious food allergy reactions in the United States.

About Oral Mucosal Immunotherapy
Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence.

About Intrommune Therapeutics
Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. There is no FDA-approved treatment for peanut allergy or any other food allergy.

For more information, please visit www.intrommune.com.

Contact:
Michelle Mantia
Outreach Manager
Intrommune Therapeutics
[email protected]